TY - JOUR
T1 - Efficacy of beetroot juice on reducing blood pressure in hypertensive adults with autosomal dominant polycystic kidney disease (BEET-PKD)
T2 - study protocol for a double-blind, randomised, placebo-controlled trial
AU - Sagar, Priyanka S.
AU - Munt, Alexandra
AU - Saravanabavan, Sayanthooran
AU - Vahedi, Farnoosh Asghar
AU - Elhindi, James
AU - Nguyen, Beatrice
AU - Chau, Katrina
AU - Harris, David C.
AU - Lee, Vincent
AU - Sud, Kamal
AU - Wong, Nikki
AU - Rangan, Gopala K.
N1 - Crown Copyright 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2023/7/29
Y1 - 2023/7/29
N2 - Background: In autosomal dominant polycystic kidney disease (ADPKD) impaired nitric oxide (NO) synthesis, in part, contributes to early-onset hypertension. Beetroot juice (BRJ) reduces blood pressure (BP) by increasing NO-mediated vasodilation. The aim of this double-blind, randomised, placebo-controlled study is to test the hypothesis that BRJ reduces systolic and diastolic clinic BP in hypertensive adults with ADPKD.Methods: Participants with ADPKD and treated hypertension (n = 60) will be randomly allocated (1:1) to receive a daily dose of either nitrate-replete (400 mg nitrate/day) or nitrate-deplete BRJ for 4 weeks. The co-primary outcomes are change in mean systolic and diastolic clinic BP before and after 4 weeks of treatment with daily BRJ. Secondary outcomes are changes in daily home BP, urinary albumin to creatinine ratio, serum and salivary nitrate/nitrite levels and serum asymmetric dimethylarginine levels before and after 4 weeks of BRJ.Discussion: The effect of BRJ in ADPKD has not been previously tested. BRJ is an accessible, natural dietary supplement that, if effective, will provide a novel adjunctive approach for treating hypertension in ADPKD.Trial registration: ClinicalTrials.gov NCT05401409. Retrospectively registered on 27th May 2022.
AB - Background: In autosomal dominant polycystic kidney disease (ADPKD) impaired nitric oxide (NO) synthesis, in part, contributes to early-onset hypertension. Beetroot juice (BRJ) reduces blood pressure (BP) by increasing NO-mediated vasodilation. The aim of this double-blind, randomised, placebo-controlled study is to test the hypothesis that BRJ reduces systolic and diastolic clinic BP in hypertensive adults with ADPKD.Methods: Participants with ADPKD and treated hypertension (n = 60) will be randomly allocated (1:1) to receive a daily dose of either nitrate-replete (400 mg nitrate/day) or nitrate-deplete BRJ for 4 weeks. The co-primary outcomes are change in mean systolic and diastolic clinic BP before and after 4 weeks of treatment with daily BRJ. Secondary outcomes are changes in daily home BP, urinary albumin to creatinine ratio, serum and salivary nitrate/nitrite levels and serum asymmetric dimethylarginine levels before and after 4 weeks of BRJ.Discussion: The effect of BRJ in ADPKD has not been previously tested. BRJ is an accessible, natural dietary supplement that, if effective, will provide a novel adjunctive approach for treating hypertension in ADPKD.Trial registration: ClinicalTrials.gov NCT05401409. Retrospectively registered on 27th May 2022.
KW - Polycystic kidney disease
KW - Beetroot juice
KW - Dietary interventions in hypertension
UR - http://www.scopus.com/inward/record.url?scp=85166003444&partnerID=8YFLogxK
U2 - 10.1186/s13063-023-07519-2
DO - 10.1186/s13063-023-07519-2
M3 - Article
C2 - 37507763
SN - 1745-6215
VL - 24
SP - 1
EP - 12
JO - Trials
JF - Trials
IS - 1
M1 - 482
ER -